Skip to main content

Devolving national pay for performance programmes

Primary health care services are important in establishing an effective, efficient, and equitable health system and in improving population health. This has led governments in many countries to increase their investment in primary care and introduce initiatives to improve quality, such as pay for performance. In the United Kingdom, this includes the Quality & Outcomes Framework (QOF), a national pay for performance programme. There is interest in devolving some aspects of national pay for performance programmes to local primary care organisations, to give greater flexibility and the ability to focus on local priorities. In a recent BMJ paper, Christopher Millett and colleagues discuss one such local programme, QOF+, which was implemented in NHS Hammersmith & Fulham.

The review of the scheme in NHS Hammersmith & Fulham suggests that local pay for performance incentive schemes may allow for opportunities to improve quality, encourage innovation, and tackle local public health priorities. An integrated incentive scheme such as QOF+ could also replace the plethora of disparate incentive schemes currently in place in primary care organisations  However, there are also disadvantages of such schemes. They can require considerable investment in both time and money, and their widespread adoption is unlikely without the government devolving part of the national QOF budget to primary care organisations for local priorities, expediting plans to develop a national menu of quality indicators for local use, and having an information technology infrastructure that allows for the monitoring and evaluation of such schemes.

Hence, there are advantages and disadvantages to such local incentive schemes and their wider roll-out and implementation would need careful monitoring.


Popular posts from this blog

Improving discharge planning in NHS hospitals

Factors that need to be considered in discharge planning that have been identified in previous projects include:

Ensuring that discharge arrangements are discussed with patients, family members and carers; and that they are given a copy of the discharge summary.Adequate coordination between the hospital, community health services, general practices, and the providers of social care services.There is a follow-up after discharge of patients at high risk of complications or readmission - either in person or by telephone - to ensure that the discharge arrangements are working well. Medicines reconciliation is carried out. This is the process of verifying patient medication lists at a point-of-care transition, such as hospital discharge, to identify which medications have been added, discontinued, or changed from pre-admission medication lists.Ensuring that any outstanding test results at discharge are obtained and passed on to primary care teams; and ensuring there are clear arrangements …

Can GPs issue private prescriptions to NHS patients?

The NHS prescription charge in England is currently £8.40 per item. At this level, many commonly prescribed drugs will cost less than the prescription charge and so some NHS patients may occasionally ask if they can have a private prescription rather than an NHS prescription.

In the past, some GPs have been advised that they could issue both an NHS FP10 and a private prescription, and let the patient decide which to use. But the British Medical Association's General Practice Committee has obtained legal advice that said under the current primary care contract, GPs in England may not issue a private prescription alongside or as an alternative to an NHS FP10 prescription. In any consultation where a GP needs to issue an FP10, the concurrent issue of a private prescription would be a breach of NHS regulations.

The issuing of a private prescription in such circumstances could also be seen as an attempt to deprive the NHS of the funds it would receive from the prescription charge. Fur…

What impact will Brexit have on the UK's life sciences sector?

On Thursday 3 November 2016, I spoke at a seminar at the Imperial College Business School on the topic of the impact of Brexit on the UK's life sciences sector (the NHS, universities, and pharmaceutical and biomedical companies). I emphasised the important role played in the life sciences sector by EU-trained professionals and the need to ensure that the UK continued to attract highly-qualified professionals to work, for example, in our National Health Service. I also discussed the need to increase spending on research and development to ensure that the UK remained a world leader in the biomedical industry. The other speakers at the seminar were Andrew Lansley (former Secretary of State for Health) and Richard Phillips (Director of Healthcare Policy at the Association of British Healthcare industries). The event was chaired by Andrew Brown. A copy of my talk can be viewed on Slideshare.